Showing promise in the field of obesity management, retatrutide presents a different approach. Beyond many existing medications, retatrutide operates as a dual agonist, simultaneously targeting both glucagon-like peptide-1 (GLP-1) and glucose-responsive insulinotropic substance (GIP) receptors. This dual stimulation fosters several beneficial effec